查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1798780

全球足底筋膜炎治疗市场成长、规模和趋势分析：展望、竞争策略以及按治疗类型、适应症、最终用户和地区分類的预测（至 2034 年）

Global Plantar Fasciitis Treatment Market Growth, Size, Trends Analysis - By Treatment Type, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 242 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计到 2034 年全球足底筋膜炎治疗市场规模将达到 32.7 亿美元，复合年增长率为 9.57%。

足底筋膜炎的治疗包括多种疗法，旨在缓解症状并解决根本病因。足底筋膜炎是一种常见的足部疾病，其特征是足底筋膜（一条沿着足底从跟骨延伸至足趾的厚组织带）的发炎和刺激。

阻碍因素：足底筋膜炎治疗市场扩张的因素包括衝击波疗法和手术等先进治疗方法费用高昂，对经济条件较差地区的患者可能造成负担。此外，大众对足底筋膜炎及其治疗方法缺乏认知，也是市场扩张的一大障碍。

本报告调查了全球足底筋膜炎治疗市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场、地区/主要国家的详细分析、竞争格局以及主要企业的概况。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场动态

  • 驱动因素、阻碍因素、机会与挑战分析

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争态势

  • 製造地、销售区域、产品类型分布
  • 併购、合作伙伴关係、产品发布和合作

7. 全球足底筋膜炎治疗市场（依治疗类型）

  • 治疗方法
    • 矫正器具
    • 衝击波疗法
    • 超音波治疗
    • 其他的
  • 药物治疗
    • 非类固醇消炎剂（NSAID）
    • 皮质类固醇注射
    • 局部止痛药
  • 外科手术
    • 足底筋膜切开术
    • 腓肠肌（小腿腹部）延长
    • 肌腱转移

8. 全球足底筋膜炎治疗市场（按适应症）

  • 温和的
  • 缓和
  • 严重

9. 全球足底筋膜炎治疗市场（依最终用户）

  • 医院
  • 整形外科诊所
  • 物理治疗中心
  • 其他的

第 10 章：全球足底筋膜炎治疗市场

  • 全球市场规模和市场占有率

第 11 章全球足底筋膜炎治疗市场（按地区）

  • 亚太地区
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他的
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 埃及
    • 摩洛哥
    • 奈及利亚
    • 其他的
  • 北美洲
    • 加拿大
    • 墨西哥
    • 美国
  • 拉丁美洲
    • 阿根廷
    • 巴西
    • 其他的

第十二章：公司简介

  • 3M
  • Algeo Ltd
  • Bauerfeind USA Inc
  • Hanger, Inc
  • OrthoBethesda
  • OrthoMed, Inc
  • Ottobock
  • Pfizer, Inc
  • Revance Therapeutics, Inc
  • Sanofi
  • 其他的

第十三章 结论

第 14 章简称列表

第 15 章参考链接

简介目录
Product Code: HLCA25223

Plantar Fasciitis Treatment Market Introduction and Overview

According to SPER market research, 'Global Plantar Fasciitis Treatment Market Size- By Treatment Type, By Indication, By End-User - Regional Outlook, Competitive Strategies and Segment Forecast to 2034' state that the Global Plantar Fasciitis Treatment Market is predicted to reach 3.27 billion by 2034 with a CAGR of 9.57%.

Plantar fasciitis treatment encompasses a range of therapeutic approaches aimed at relieving symptoms and addressing the root causes of plantar fasciitis, which is a prevalent foot condition marked by inflammation and irritation of the plantar fascia. This thick band of tissue extends along the foot's base, connecting the heel bone to the toes.

Restraints: Factors impeding the treatment market for plantar fasciitis involve the substantial expense associated with advanced therapies, including shock wave therapy and surgical options, which may be financially daunting for certain patients, particularly in economically disadvantaged areas. Furthermore, the insufficient awareness regarding plantar fasciitis and its corresponding treatments among various individuals is obstructing market expansion.

Scope of the report:

Report Metric Details

Market size available for years 2021-2034

Base year considered 2024

Forecast period 2025-2034

Segments covered By Treatment Type, By Indication, By End-User

Regions covered North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa

Companies Covered 3M, A. Algeo Ltd, Bauerfeind USA Inc, Hanger, Inc, OrthoBethesda, OrthoMed, Inc, Ottobock, Pfizer, Inc, Revance Therapeutics, Inc, Sanofi.

Global Plantar Fasciitis Treatment Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Plantar Fasciitis Treatment Market is segmented as; Therapy, Medication Therapy, Surgery.

By Indication: Based on the Indication, Global Plantar Fasciitis Treatment Market is segmented as; Mild, Moderate, Severe.

By End-User: Based on the End-User, Global Plantar Fasciitis Treatment Market is segmented as; Hospitals, Orthopedic Clinics, Physiotherapy Centers, Other End-User.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPERs internal database
    • 2.1.4. Premium insight from KOLs
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTERs Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Plantar Fasciitis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Plantar Fasciitis Treatment Market

7. Global Plantar Fasciitis Treatment Market, By Treatment Type (USD Million) 2021-2034

  • 7.1. Therapy
    • 7.1.1. Orthotic devices
    • 7.1.2. Shockwave therapy
    • 7.1.3. Ultrasound therapy
    • 7.1.4. Other therapies
  • 7.2. Medication Therapy
    • 7.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDs)
    • 7.2.2. Corticosteroid injections
    • 7.2.3. Topical pain relievers
  • 7.3. Surgery
    • 7.3.1. Plantar fascia release
    • 7.3.2. Gastrocnemius recession
    • 7.3.3. Tendon transfer

8. Global Plantar Fasciitis Treatment Market, By Indication (USD Million) 2021-2034

  • 8.1. Mild
  • 8.2. Moderate
  • 8.3. Severe

9. Global Plantar Fasciitis Treatment Market, By End-User (USD Million) 2021-2034

  • 9.1. Hospitals
  • 9.2. Orthopedic Clinics
  • 9.3. Physiotherapy Centers
  • 9.4. Other End-User

10. Global Plantar Fasciitis Treatment Market, (USD Million) 2021-2034

  • 10.1. Global Plantar Fasciitis Treatment Market Size and Market Share

11. Global Plantar Fasciitis Treatment Market, By Region, (USD Million) 2021-2034

  • 11.1. Asia-Pacific
    • 11.1.1. Australia
    • 11.1.2. China
    • 11.1.3. India
    • 11.1.4. Japan
    • 11.1.5. South Korea
    • 11.1.6. Rest of Asia-Pacific
  • 11.2. Europe
    • 11.2.1. France
    • 11.2.2. Germany
    • 11.2.3. Italy
    • 11.2.4. Spain
    • 11.2.5. United Kingdom
    • 11.2.6. Rest of Europe
  • 11.3. Middle East and Africa
    • 11.3.1. Kingdom of Saudi Arabia
    • 11.3.2. United Arab Emirates
    • 11.3.3. Qatar
    • 11.3.4. South Africa
    • 11.3.5. Egypt
    • 11.3.6. Morocco
    • 11.3.7. Nigeria
    • 11.3.8. Rest of Middle-East and Africa
  • 11.4. North America
    • 11.4.1. Canada
    • 11.4.2. Mexico
    • 11.4.3. United States
  • 11.5. Latin America
    • 11.5.1. Argentina
    • 11.5.2. Brazil
    • 11.5.3. Rest of Latin America

12. Company Profile

  • 12.1. 3M
    • 12.1.1. Company details
    • 12.1.2. Financial outlook
    • 12.1.3. Product summary
    • 12.1.4. Recent developments
  • 12.2. Algeo Ltd
    • 12.2.1. Company details
    • 12.2.2. Financial outlook
    • 12.2.3. Product summary
    • 12.2.4. Recent developments
  • 12.3. Bauerfeind USA Inc
    • 12.3.1. Company details
    • 12.3.2. Financial outlook
    • 12.3.3. Product summary
    • 12.3.4. Recent developments
  • 12.4. Hanger, Inc
    • 12.4.1. Company details
    • 12.4.2. Financial outlook
    • 12.4.3. Product summary
    • 12.4.4. Recent developments
  • 12.5. OrthoBethesda
    • 12.5.1. Company details
    • 12.5.2. Financial outlook
    • 12.5.3. Product summary
    • 12.5.4. Recent developments
  • 12.6. OrthoMed, Inc
    • 12.6.1. Company details
    • 12.6.2. Financial outlook
    • 12.6.3. Product summary
    • 12.6.4. Recent developments
  • 12.7. Ottobock
    • 12.7.1. Company details
    • 12.7.2. Financial outlook
    • 12.7.3. Product summary
    • 12.7.4. Recent developments
  • 12.8. Pfizer, Inc
    • 12.8.1. Company details
    • 12.8.2. Financial outlook
    • 12.8.3. Product summary
    • 12.8.4. Recent developments
  • 12.9. Revance Therapeutics, Inc
    • 12.9.1. Company details
    • 12.9.2. Financial outlook
    • 12.9.3. Product summary
    • 12.9.4. Recent developments
  • 12.10. Sanofi
    • 12.10.1. Company details
    • 12.10.2. Financial outlook
    • 12.10.3. Product summary
    • 12.10.4. Recent developments
  • 12.11. Others

13. Conclusion

14. List of Abbreviations

15. Reference Links